235 related articles for article (PubMed ID: 35197929)
1. [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
[TBL] [Abstract][Full Text] [Related]
2. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
3. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
5. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
6.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
Naji M; Zhao C; Welsh SJ; Meades R; Win Z; Ferrarese A; Tan T; Rubello D; Al-Nahhas A
Mol Imaging Biol; 2011 Aug; 13(4):769-75. PubMed ID: 20700766
[TBL] [Abstract][Full Text] [Related]
8. Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [
Gubbi S; Al-Jundi M; Auh S; Jha A; Zou J; Shamis I; Meuter L; Knue M; Turkbey B; Lindenberg L; Mena E; Carrasquillo JA; Teng Y; Pacak K; Klubo-Gwiezdzinska J; Del Rivero J; Lin FI
Front Endocrinol (Lausanne); 2023; 14():1275813. PubMed ID: 37886645
[TBL] [Abstract][Full Text] [Related]
9. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
10. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
Jungels C; Karfis I
Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
12. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
14. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
15. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
[TBL] [Abstract][Full Text] [Related]
16. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
17. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
18. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
[TBL] [Abstract][Full Text] [Related]
20. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Pandit-Taskar N; Chen CC
Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]